Trial Profile
A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Orally Administered AK0529 in Adults With Respiratory Syncytial Virus Infection
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Ziresovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASCENT
- Sponsors Ark Biosciences
- 29 Dec 2018 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 New trial record